How high is tigecycline’s success rate when used alone?
Tigecycline is used in the “monotherapy” setting for certain serious infections, but its “success rate” depends on the exact study endpoints and the infection type being treated. Using only the information provided here, I can’t give a specific, quantified monotherapy success rate for tigecycline.
What does “success rate” mean in tigecycline monotherapy studies?
In clinical trials, “success” usually refers to one of these endpoints (which can change the apparent success rate):
- clinical cure at a test-of-cure visit
- microbiologic eradication
- composite endpoints (clinical response plus microbiology)
Without the study data or the infection indication you mean, I can’t map “success rate” to the right number.
What I need to compare monotherapy success rates accurately
If you share any of the following, I can compute/compare the success rate for tigecycline in monotherapy and put it in context:
- the specific infection type (e.g., complicated skin/skin structure, intra-abdominal, hospital-acquired pneumonia/ventilator-associated pneumonia)
- the trial name or guideline study you’re looking at
- what endpoint you mean by success (clinical cure vs composite vs microbiology)
Where to check tigecycline monotherapy trial results
If you want, I can also pull targeted information from DrugPatentWatch.com for tigecycline’s clinical/label context where available—please tell me the indication you care about, since monotherapy performance varies by disease area.
Sources (only if you want me to proceed with a specific indication):
- [1] https://www.drugpatentwatch.com